Aim: Polycystic ovary syndrome (PCOS) is a significant risk factor for premenopausal endometrial cancer (EC) and/or atypical endometrial hyperplasia (AEH). The aim was to elucidate the clinical background and detailed menstrual history of EC and/or AEH in young women with PCOS. Medroxyprogesterone acetate therapy was not effective for the patients with PCOS and they underwent a hysterectomy more often than the patients without PCOS. All the patients with PCOS exhibited irregular menstruation or amenorrhea, the mean duration of which was 13.1 years before PCOS and EC and/or AEH were diagnosed.
| MATERIALS AND METHODS
Between January 2001 and December 2013, hospital records were used to identify a cohort of patients who were under 35 years of age, who had been diagnosed with EC and/or AEH, and who had been treated at Kumamoto University Hospital, Japan. A retrospective observational study was conducted. The clinical characteristics, pathological diagnosis of EC and/or AEH, conservative treatment or hysterectomy, endocrine profiles, and menstrual history were assessed retrospectively from the medical records.
The study's participants were divided into two groups, a PCOS group and a non-PCOS group, and PCOS was diagnosed by using the revised criteria that were proposed by the Japanese Society of Obstetrics and Gynecology (JSOG) in 2007. 12 , 13 The patients who had been treated prior to the criteria undergoing this revision were re-examined and the diagnosis of PCOS was reconfirmed. Table 3 ). The five cases that were identified with AEH were all patients without PCOS. The number of patients who had undergone conservative therapy with MPA was six (43%) and nine (82%) in the PCOS group and the non-PCOS group, respectively. In the PCOS group, MPA therapy was effective in two out of six (33%)
cases, but eight out of nine (89%) cases in the non-PCOS group (P<.05) ( Table 4 ). All the patients with stage IB and above underwent a hysterectomy. There were 13 and five cases of stage IA in the PCOS group and non-PCOS group, respectively. When limited to stage IA, dilatation and curettage as a fertility-sparing treatment was performed in only two out of 13 cases in the PCOS group, whereas four out of five patients in the non-PCOS group underwent this procedure. When the operation method was compared between the two groups, it was clear that the non-PCOS group participants were more likely to preserve their fecundity than the PCOS group participants (P=.0007) ( Table 5) . Among the 25 participants, 22 (88%) exhibited a history of oligomenorrhea or amenorrhea. At the time of the EC and/or AEH diagnosis, all 14 patients with PCOS had oligomenorrhea or amenorrhea, whereas eight out of 11 of the patients without PCOS had oligomenorrhea or amenorrhea. In the PCOS group, 11 out of 14 cases had irregular menstruation or amenorrhea during their adolescent period.
The mean duration of oligomenorrhea or amenorrhea was 13.1 years (median: 16; range: 1-21) and 10.1 years (median: 10; range: 0-21) before been diagnosed with EC and/or AEH in the PCOS group and the non-PCOS group, respectively (P=.335) (Fig. 1 ). The serum PRL, however, was non-significantly higher in the non-PCOS group than in the PCOS group. As elevated serum PRL levels are one of the major causes of irregular menstruation and as PRL might be important in the development of early neoplastic transformation, such as endometrial hyperplasia, 15 it follows that hyperprolactinemia might be an independent risk factor for premenopausal EC and/or AEH in the study's non-PCOS group.
| DISCUSSION
When comparing the characteristics of EC and/or AEH by clinical stages and MPA therapy or surgical treatment between the PCOS group and the non-PCOS group, it was apparent that the PCOS group did not have AEH and that the patients in this group were less likely to have MPA therapy and fertility-sparing surgery, even in the samestage IA. This result supports the idea that obesity and insulin resistance are independent risk factors for premenopausal EC and/or AEH.
16
Chronic anovulation is one of the major risk factors for premenopausal EC and/or AEH. In the present study, 88% (22 out of 25) of the patients had irregular menstrual cycles that were suggestive of chronic anovulation. Although both the number of irregular menstruation cycles and the mean duration of oligomenorrhea or amenorrhea were not significantly different between the PCOS and non-PCOS groups, the PCOS group tended to have longer irregular menstruation or amenorrhea in their adolescent period. Therefore, this might be the reason for the PCOS group to be less likely to have fertility-sparing surgery. However, the diagnosis of PCOS in adolescents is difficult because the features of early normal pubertal development and PCOS are often similar. 17 Ultrasonography is less practical for the diagnosis of polycystic ovaries in adolescent girls, as the ovarian appearance and volume can vary during adolescence and the trans-vaginal modality is less preferred than the trans-abdominal approach. 18 Although irregular menstrual cycles in the 5 years after menarche are physiological 20 The diagnosis of PCOS is more difficult in the Asian population because hyperandrogenism is not as apparent as in the Caucasian population. Consequently, taking a menstrual history is likely to be the most powerful clue with which to diagnose PCOS. It has been suggested that anovulatory adolescents, even those who do not meet the criteria for a diagnosis of PCOS, should be followed up carefully and might be diagnosed at a later time.
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In conclusion, PCOS is frequently found among patients with EC and/or AEH who are under 35 years of age. These patients are more often obese, insulin-resistant, and less likely to have undergone fertility-sparing surgery than are patients without PCOS because they had more advanced disease or failed to respond to MPA therapy.
Patients with PCOS exhibit a year-long duration of oligomenorrhea or amenorrhea prior to the diagnosis of PCOS. Therefore, early diagnosis and appropriate treatment are vital in the prevention of EC and/or AEH and in fertility preservation in patients with PCOS who are under 35 years of age.
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